This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Griepp , MD Professor in Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai , was named as the new President of the HeartValve Society ( HVS ) at the 2024 HVS Annual Meeting on Wednesday, February 21, in Boston.
mtaschetta-millane Mon, 07/29/2024 - 09:02 July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing patient care through structural heartinnovation, addressing large unmet patient needs and supporting sustainable long-term growth.
Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heartvalve, for which more than 1.6 TR occurs when the valve doesn't close properly, causing a leak and allowing blood to flow backward in the heart. Abbott has announced U.S million people in the U.S.
Tricuspid and mitral valves are debilitating conditions that can lead to arrhythmias, hypertension, and heartfailure. Until recently, therapeutic options for people with tricuspid and mitral valve disorders have been limited to symptom relief or high-risk surgery.
Catheter-based procedures offer an alternative for patients who are not candidates for open-heart surgery. Raj Makkar, MD: Tricuspid regurgitation is a condition where the tricuspid valve fails to close properly, allowing blood to flow backward into the right atrium.
Tricuspid regurgitation (TR) is a common and serious disease for which open heart surgery and symptomatic pharmacologic treatment are the current standard treatment options. Topaz is an innovative, minimally invasive device designed specifically to help patients suffering from severe TR, without the need for open heart surgery.
suffer from heartfailure , and there are approximately 400,000 heart-failure-related deaths in this country each year. Patients with heartfailure often experience reduced mobility, quality of life and ability to work; the disease also represents a significant public health care burden.
milla1cf Tue, 04/23/2024 - 15:53 April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. This next-generation surgical aortic tissue valve is designed to facilitate ease of use at implant and lifetime patient management.
Getty Images milla1cf Thu, 06/13/2024 - 20:38 June 13, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest innovation in cardiac surgery, the Avalus Ultra valve. A treatment for patients with aortic valve disease is surgical aortic valve replacement (SAVR).
Additionally, the company also offers the first fully automated 3D quantification of mitral regurgitation (MR) volumes* designed to provide reproducible, efficient analysis helps clinicians make better-informed decisions for patients with heartvalve disease. “As
Shreenivas is a frequent speaker at major scientific meetings and has been widely published in peer-reviewed journals across the structural heart, heartfailure, and coronary arenas. The Carillon Mitral Contour System is designed to treat both FMR and heartfailure in one simple, short, minimally-invasive procedure.
Tricuspid and mitral valves are debilitating conditions that can lead to arrhythmias, hypertension, and heartfailure. Until recently, therapeutic options for people with tricuspid and mitral valve disorders have been limited to symptom relief or high-risk surgery.
The potential to detect aortic stenosis through our IH technology is an exciting development that brings us a step closer to achieving the MindMics purpose to one day eliminate heartfailure as the leading cause of death globally (similar to what glucose monitoring has done to transform diabetes)." "We
Catheter-based procedures offer an alternative for patients who are not candidates for open-heart surgery. Raj Makkar, MD: Tricuspid regurgitation is a condition where the tricuspid valve fails to close properly, allowing blood to flow backward into the right atrium.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content